2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

4:30PM-6:00PM: Abstract Number: 3068

Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA

Epidemiology and Public Health II: Obesity, Cancer and Mortality

4:30PM-6:00PM: Abstract Number: 5L

Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3107

Switching from Anabolic to Catabolic Metabolism – a Novel Immunomodulatory Therapy in RA

T Cell Biology and Targets in Autoimmune Disease - Oral Session

4:30PM-6:00PM: Abstract Number: 1L

The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3079

The Characteristic Features of the Patients with Deficiency of Adenosine Deaminase 2 (DADA2)

Miscellaneous Rheumatic and Inflammatory Diseases II

4:30PM-6:00PM: Abstract Number: 3084

The Impact of Mental Health on Indicators of Disease Severity Among Patients with Inflammatory Arthritis: A Cross-Sectional and Longitudinal Investigation

Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

4:30PM-6:00PM: Abstract Number: 3054

The Impact of Obesity on Knee Osteoarthritis Symptoms and Related Biomarker Profiles in a Bariatric Surgery Cohort

ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

4:30PM-6:00PM: Abstract Number: 3098

The Occurrence of Peripheral Arthritis Mutilans in Psoriatic Arthritis Is Associated with Certain Major Histocompatibility Class I Alleles

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical

4:30PM-6:00PM: Abstract Number: 3067

Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA

Epidemiology and Public Health II: Obesity, Cancer and Mortality

4:30PM-6:00PM: Abstract Number: 3055

Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricaemia: Comparison with Normouricaemic Individuals

ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

4:30PM-6:00PM: Abstract Number: 3062

Use of Script Concordance Testing to Evaluate the Efficacy of a Web-Based Module on Gout: Three Years of Experience

Education

4:30PM-6:00PM: Abstract Number: 3083

Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures

Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

4:30PM-6:00PM: Abstract Number: 3058

Varus Thrust and Incident and Progressive Knee Osteoarthritis

ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

4:30PM-6:00PM: Abstract Number: 3069

Weight Loss in the Early Rheumatoid Arthritis Period Is Associated with Subsequent Increased Mortality in RA Patients and Matched Comparators: Evidence Against an RA-Specific Obesity Paradox

Epidemiology and Public Health II: Obesity, Cancer and Mortality

4:30PM-6:00PM: Abstract Number: 3095

What Should be the Primary Target of ‘Treat to Target’ in Psa?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].